Varian Medical Systems News

The importance of reputational risk to a company and the methods of quantifying it are frequently studied and debated.

Chest surgeons will convene in San Francisco this week to learn the latest options for lung cancer treatment.

Varian Medical Systems, Inc. Bank of America Merrill Lynch Health Care Conference Call May 15, 2012 4:00 PM ET Analyst at B of A. And here with me from Varian, we have Elisha Finney, the CFO, and Spencer Sias, the Head of Investor Relations.

"We're excited about putting our technology in front of pulmonologists who may not be familiar with radiosurgery as a treatment option for early-stage, inoperable lung cancer," said , M.S., senior director of surgical sciences at Varian.

Hello. Welcome. I'm Tim Guertin. Welcome to the mid-year review for Varian Medical Systems.

More than 500 oncology professionals at European Society for Radiotherapy and Oncology congress hear of breakthrough treatments using high dose rate capability of Varian's advanced TrueBeam system with RapidArcA Radiosurgery - BARCELONA, Spain, May 11, 2012 -- European cancer experts have reported their progress with promising new radiosurgical ... (more)

Leading Radiotherapy Equipment and Software, including Advanced Brachytherapy Systems, Displayed on Booths 100 & 500, Barcelona Convention Center, May 9th-12th /PRNewswire/ -- Varian Medical Systems , the world leader in radiotherapy, is demonstrating its full range of disease specific treatment options at the 31st meeting of the European Society ... (more)

The latest issue of the journal Annals of Oncology reports that a major new study by one of the country's leading cancer centers, the VU University Medical Center in Amsterdam has revealed that widespread use of advanced radiotherapy techniques in the Netherlands has resulted in improved survival rates amongst elderly lung cancer patients.

Shares of Varian Medical Systems traded up 0.12% during mid-day trading on Wednesday, hitting $64.645. Varian Medical Systems has a one year low of $48.72 and a one year high of $71.95. The company has a market cap of $7.266 billion and a P/E ratio of 18.83. The company last announced its quarterly results on Wednesday, April 25th.

's stock had its "neutral" rating reaffirmed by Zacks in a report released on Monday.

TheA University of Pittsburgh saw its recovery in its patent infringement suit against Varian Medical Systems doubled by the judge presiding over the case, making the total amount of damages $73.6 million.